Physician profile
James C Macdonald
NPI 1851408835
$3,011.44
in general payments reported to CMS, 2019-2025
13 companies · $605 in 2025
The $605 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $21.63 · 2021: $322 · 2022: $634 · 2023: $848 · 2024: $240 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $603.42 | 2019-2025 | |
| Astellas Pharma US INC | $494.23 | 2023-2025 | Izervay |
| Genentech USA, INC. | $414.72 | 2019-2023 | Vabysmo |
| Alcon Vision LLC | $373.79 | 2020-2025 | Clareon |
| Regeneron Healthcare Solutions, INC. | $260.21 | 2022-2024 | Eylea Hd |
| Abbvie INC. | $134.59 | 2022 | |
| Apellis Pharmaceuticals, INC. | $124.99 | 2023 | Syfovre |
| Eyevance Pharmaceuticals LLC | $124.99 | 2021 | |
| Horizon Therapeutics Plc | $108.39 | 2023 | Tepezza |
| Ocular Therapeutix, INC. | $107.14 | 2022 | |
| Allergan, INC. | $104.59 | 2019 | |
| Kala Pharmaceuticals, INC. | $97.87 | 2019 | |
| Alimera Sciences, INC. | $62.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.